Want to see BIOLQ full AI Analyst Report?
BIOLASE (BIOLQ) AI Stock Analysis
Top Page
BIOLASE
(Other OTC:BIOLQ)
BIOLASE's overall stock score reflects significant financial and operational challenges, with persistent losses and cash flow issues being primary concerns. Weak technical indicators and poor valuation metrics further weigh on the stock's attractiveness. The lack of positive earnings guidance or corporate events leaves the outlook uncertain, resulting in a low overall stock score.
BIOLASE (BIOLQ) vs. SPDR S&P 500 ETF (SPY)
Not enough price history over this period.
- Market Cap
- $37
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- ―
- Beta (1Y)
- 166.27
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 157
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical Equipment & Supplies
BIOLASE Business Overview & Revenue Model
Company Description
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Wa...
How the Company Makes Money
BIOLASE generates revenue primarily through the sale of its dental laser systems and related accessories. The company offers a variety of laser products tailored to different dental needs, which are sold directly to dental professionals and through d...
BIOLASE Earnings Call Summary
The earnings call reflects a positive outlook with notable achievements in market penetration and cost reduction, despite some challenges in the economic environment and slow technology adoption. The company remains optimistic about achieving its growth and profitability targets.
Q1-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the BIOLASE Q1 2024 earnings call, executives provided detailed guidance and performance metrics, highlighting a strong quarter for the company. John Beaver, President and CEO, underscored the growing adoption of their laser technology, noting that 67% of U.S. Waterlase sales were to new customers, with 42% attributed to dental specialists, amidst a significant untapped market where over 90% of dentists have yet to adopt all-tissue laser technology. The company maintained a 60% global market share and saw consumable sales increase by 14% year-over-year, marking the third strongest quarter for consumable sales. Operational improvements led to a 21% reduction in adjusted EBITDA loss, and cost-saving strategies yielded a 9% decrease in operating expenses. CFO Jennifer Bright reaffirmed full-year guidance with expected revenue growth of 6% to 8%, targeting $52 million to $53 million, and projected achieving positive adjusted EBITDA for the year, driven by cost reductions, price increases, and enhanced operational efficiency.
BIOLASE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOLQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, compared to the 50-day MA of , and compared to the 200-day MA of , indicating a neutral trend. The MACD of -0.00 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOLQ.
BIOLASE Risk Analysis
BIOLASE disclosed 7 risk factors in its most recent earnings report. BIOLASE reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBIOLASE Peers Comparison
Overall Rating
BJDX44Neutral
DRMA42Neutral
INAB38Underperform- BIOLQ32Underperform
ENVB26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BJDX | 44Neutral | $2.49M | -0.05 | -125.01% | ― | ― | 93.91% |
| DRMA | 42Neutral | $3.84M | -0.18 | -166.67% | ― | ― | 88.77% |
| INAB | 38Underperform | $8.89M | -0.48 | -91.18% | ― | ― | 81.87% |
| BIOLQ | 32Underperform | $37 | ― | ― | ― | ― | ― |
| ENVB | 26Underperform | $6.40M | -0.09 | -168.05% | ― | ― | 87.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIOLQ | Biolase Inc | ― | ― | ― | |
| ENVB | Enveric Biosciences, Inc. | 1.43 | -5.65 | -79.80% | |
| INAB | In8bio, Inc. | 0.90 | -0.98 | -52.07% | |
| DRMA | Dermata Therapeutics, Inc. | 0.78 | -2.65 | -77.34% | |
| BJDX | Bluejay Diagnostics, Inc. | 0.56 | -6.56 | -92.19% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 01, 2025